CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Update

CytoDyn Inc. (OTCMKTS:CYDY) saw a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 4,680,600 shares, a decrease of 8.4% from the March 15th total of 5,107,100 shares. Based on an average daily volume of 2,871,500 shares, the days-to-cover ratio is currently 1.6 days.

CytoDyn Trading Down 7.6 %

CytoDyn stock traded down $0.01 during mid-day trading on Tuesday, hitting $0.15. 4,669,367 shares of the company’s stock were exchanged, compared to its average volume of 1,300,729. CytoDyn has a 1-year low of $0.13 and a 1-year high of $0.42. The stock has a 50 day moving average of $0.17 and a two-hundred day moving average of $0.18. The stock has a market cap of $143.97 million, a P/E ratio of -2.42 and a beta of 0.17.

CytoDyn (OTCMKTS:CYDY) last issued its quarterly earnings data on Monday, April 15th. The biotechnology company reported ($0.01) EPS for the quarter.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.